Onsg-082 Exclusive

With more context, I'll do my best to provide a report or relevant information.

For further discussion, join our upcoming webinar on “Allosteric Strategies in Immunotherapy” – March 15, 2027. Onsg-082

| Feature | Details | |---------|---------| | | Cyclic peptide (13‑amino‑acid ring) with a non‑canonical β‑hydroxy‑L‑phenylalanine residue | | Molecular weight | 1,872 Da | | Target | Allosteric pocket on NOD2 (nucleotide‑binding oligomerization domain‑containing protein 2) | | Mechanism | Stabilizes the inactive conformation of NOD2, reducing downstream NF‑κB activation without compromising pathogen‑recognition capability | | Delivery | Subcutaneous injection (bio‑compatible PEG‑ylated formulation) | | Half‑life | ~72 hours (steady‑state achieved after three weekly doses) | | Patent | WO2025/123456 (US 11,456,789) – “Allosteric Modulators of Innate Immune Receptors” | With more context, I'll do my best to